Literature DB >> 9392299

Characterization of pigs transgenic for human decay-accelerating factor.

E Cozzi1, A W Tucker, G A Langford, G Pino-Chavez, L Wright, M J O'Connell, V J Young, R Lancaster, M McLaughlin, K Hunt, M C Bordin, D J White.   

Abstract

BACKGROUND: To prevent the central role played by complement activation in the hyperacute rejection of pig organs transplanted into primates, pigs transgenic for human decay-accelerating factor (HDAF) have recently been produced. The data presented here extend previous immunohistochemical findings by documenting the immunological characterization and the levels of expression of HDAF in these transgenic pigs.
METHODS: Animals from 30 independently derived lines were included in this study. HDAF expression was characterized by immunoprecipitation and epitope mapping. Quantitative analysis was performed by radiometric assays followed by Scatchard analysis and by double-determinant radioimmunoassay. Deposition of iC3b on porcine aortic endothelial cells was determined by radioimmunoassay. DNA slot-blot analysis and densitometric scanning were used to evaluate HDAF transgene copy number.
RESULTS: The integrity of HDAF expressed by these transgenic pigs could be demonstrated. HDAF was present in 72% of the organs analyzed, although considerable variation in expression occurred, both between animals and within the same pig. High levels of HDAF on porcine aortic endothelial cells resulted in iC3b deposition at levels as low as that detected on human endothelial cells. Twenty-six organs expressed levels of HDAF greater than those observed in the equivalent human tissue. HDAF expression did not correlate with the number of copies of the transgene incorporated into the porcine genome.
CONCLUSIONS: Transgenic pigs, which express levels of functional HDAF even greater than those observed in humans, have successfully been produced. Pigs transgenic for human complement inhibiting molecules could represent a source of organs for future clinical xenotransplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9392299     DOI: 10.1097/00007890-199711270-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  22 in total

1.  Inside the mouse hospital: science, animal welfare and strife in the drive for AAALAC accreditation.

Authors:  V Hampshire; J Davis
Journal:  Transgenic Res       Date:  1999-08       Impact factor: 2.788

2.  Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA.

Authors:  Vannary Tieng; Chantal Le Bouguénec; Laurence du Merle; Philippe Bertheau; Pierre Desreumaux; Anne Janin; Dominique Charron; Antoine Toubert
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

3.  Efficient production by sperm-mediated gene transfer of human decay accelerating factor (hDAF) transgenic pigs for xenotransplantation.

Authors:  Marialuisa Lavitrano; Maria Laura Bacci; Monica Forni; Davide Lazzereschi; Carla Di Stefano; Daniela Fioretti; Paola Giancotti; Gabriella Marfé; Loredana Pucci; Luigina Renzi; Hongjun Wang; Antonella Stoppacciaro; Giorgio Stassi; Massimo Sargiacomo; Paola Sinibaldi; Valeria Turchi; Roberto Giovannoni; Giacinto Della Casa; Eraldo Seren; Giancarlo Rossi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-22       Impact factor: 11.205

Review 4.  An update on xenotransplantation.

Authors:  E Cozzi; M Seveso; S Hutabba; S Fabris; L Cavicchioli; E Ancona
Journal:  Vet Res Commun       Date:  2007-08       Impact factor: 2.459

5.  Therapeutic potential of porcine bronchoalveolar fluid-derived mesenchymal stromal cells in a pig model of LPS-induced ALI.

Authors:  Mahesh Khatri; Levi A Richardson
Journal:  J Cell Physiol       Date:  2018-01-19       Impact factor: 6.384

6.  On the intersections of basic and applied research in xenotransplantation.

Authors:  Agustin P Dalmasso
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

7.  Protection against hyperacute xenograft rejection of transgenic rat hearts expressing human decay accelerating factor (DAF) transplanted into primates.

Authors:  B Charreau; S Ménoret; L Tesson; A Azimzadeh; M Audet; P Wolf; R Marquet; C Verbakel; J Ijzermans; P Cowan; M Pearse; A d'Apice; J P Soulillou; I Anegon
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

8.  Development of a consensus protocol to quantify primate anti-non-Gal xenoreactive antibodies using pig aortic endothelial cells.

Authors:  Agnes M Azimzadeh; Guerard W Byrne; Mohamed Ezzelarab; Emily Welty; Gheorghe Braileanu; Xiangfei Cheng; Simon C Robson; Christopher G A McGregor; David K C Cooper; Richard N Pierson
Journal:  Xenotransplantation       Date:  2014-09-01       Impact factor: 3.907

9.  New Strategies for Acute Liver Failure: Focus on Xenotransplantation Therapy.

Authors:  Luiz Anastácio Alves; André Bonavita; Kátia Quaresma; Elenilde Torres; Paulo Anastácio Furtado Pacheco; Vinícius Cotta-de-Almeida; Roberto Magalhães Saraiva
Journal:  Cell Med       Date:  2010-07-01

Review 10.  Pig liver xenotransplantation as a bridge to allotransplantation: which patients might benefit?

Authors:  Burcin Ekser; Bruno Gridelli; A Joseph Tector; David K C Cooper
Journal:  Transplantation       Date:  2009-11-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.